Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamrevlumab - FibroGen

Next Previous
Drug Profile

Pamrevlumab - FibroGen

Alternative Names: Anti-CTGF antibody - FibroGen; FG-3019

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FibroGen
  • Class Antifibrotics; Antineoplastics; Antivirals; Cardiovascular therapies; Immunotherapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Pancreatic cancer; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued COVID 2019 infections; Diabetic cardiomyopathy; Diabetic nephropathies; Diabetic neuropathies; Duchenne muscular dystrophy; Glioblastoma; Glomerulonephritis; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Pancreatic cancer

Most Recent Events

  • 05 Feb 2025 Pancreatic Cancer Action Network completes the Phase-II/III clinical trials in Pancreatic cancer (Second-line therapy or greater, First-line therapy, Metastatic disease, Combination therapy) in USA (IV) (NCT04229004)
  • 30 Jul 2024 Discontinued - Phase-II for COVID-2019 infections in USA (IV)
  • 30 Jul 2024 Discontinued - Phase-II for Idiopathic pulmonary fibrosis in Canada, New Zealand, India, Bulgaria, Australia, South Africa (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top